HOME >> MEDICINE >> NEWS
Evidence of PSA screening efficacy lacking

There is no evidence to support speculation that prostate-specific antigen (PSA) screening has contributed to a decline in prostate cancer mortality rates since 1995, a new study has determined. The value of such screening remains controversial. Some American authorities have called for cancer screening in men who ask about the PSA test, while the Canadian Urological Association and most health authorities in Europe still discourage it. The number of men becoming candidates for such screening is growing rapidly because of the aging of the baby-boom generation. Dr. Franois Meyer and colleagues divided the adult males of Quebec who were 50 years or older into 15 birth cohorts and computed the change in prostate cancer incidence between 1989 and 1993, and the change in prostate cancer mortality between 1995 and 1999. They then assessed the correlation between the changes in cancer incidence and the subsequent changes in prostate cancer mortality. The authors also split the population into 15 regional populations and repeated the analysis, which yielded a similar outcome, leading them to conclude that PSA screening cannot explain the decline in prostate cancer mortality in the population studied. The authors warn that the results need to be considered with caution because PSA screening may well be shown to be an effective tool in preventing or postponing death from prostate cancer, but the evidence does not yet exist to support such a claim.

In a related commentary, Andr Vis says answers on whether PSA screening is truly beneficial at a population level will only be provided when large-scale randomized controlled trials several of which were begun in the US and Europe in the early 1990s are completed.


'"/>

Contact: Dr. Franois Meyer
francois.meyer@crhdq.ulaval.ca
418-525-4444 x5581
Canadian Medical Association Journal
4-Mar-2002


Page: 1

Related medicine news :

1. Evidence indicates cancer patients unable to intentionally postpone death for significant events
2. Not guilty! Evidence exonerates 328, but many still falsely imprisoned
3. Evidence for shaken baby syndrome is uncertain
4. Evidence suggests that the brain can switch to automatic pilot during learning
5. Evidence that memories are consolidated during sleep
6. Evidence that neurons prune only twigs to rewire themselves
7. Evidence supports two types of heart failure
8. Evidence for warts treatments is weak
9. Evidence does not support psychological treatments for epilepsy
10. DDW Studies Present Evidence That Thalomid (Thalidomide) Is Active In Treating Crohns Disease
11. Evidence Shows Drug-Psychotherapy Combo Effective For Chronic Depression

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Evidence PSA screening efficacy lacking

(Date:5/24/2013)... News) -- Drugs commonly used to treat glaucoma may ... interfere with vision, according to a new study. ... used to reduce eye pressure, have already been shown ... color, the researchers said, suggesting that the new findings ... Doctors should be conservative when prescribing these drugs, the ...
(Date:5/24/2013)... Let’s face it: very few are luckily ... the majority of people to be uncomfortable with the color ... coffee addiction or simply genetics, yellowish or stained teeth suppresses ... , Herald Square Dental is proud to announce ... Venus White Max. , Teeth become discolored for a ...
(Date:5/24/2013)... Chino, CA (PRWEB) May 24, 2013 Area ... huge selection of new hot tubs to choose from at ... Super Sale . The sales event takes place at ... May 26, 2013. , Jacuzzi, the industry's leading hot ... sale traveling across the country. The event will feature popular ...
(Date:5/24/2013)... New York (PRWEB) May 24, 2013 ... lawsuit involving Intuitive Surgical Inc.’s da Vinci Surgical ... to court records, a Washington State Court jury ruled ... negligence in training a surgeon who performed a da ... later. The patient’s family had alleged in their ...
(Date:5/24/2013)... development of infantile myofibromatosis (IM)a disorder characterized by multiple ... new therapeutic targets, according to researchers from the Icahn ... in the American Journal of Human Genetics , ... disease, for which the only current treatment option is ... an inheritied disorder that develops in infancy or even ...
Breaking Medicine News(10 mins):Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2Health News:Herald Square Dental Introduces New In-office Whitening System: Venus White Max 2Health News:Truckload of Jacuzzi® Hot Tubs Rolls into Bend, Oregon on May 24, 2013 for Sales Event 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 3Health News:Researchers identify first drug targets in childhood genetic tumor disorder 2
(Date:5/23/2013)... SAN DIEGO y PARÍS, 24 de ... VOLC ), un destacado desarrollador y fabricante ... para mejorar la diagnosis y tratamiento de la ... resultados preliminares del ensayo ADVISE ( Ad enosine ... tenosis E valuation) II durante la sesión ...
(Date:5/23/2013)... , May 23, 2013 Amgen (NASDAQ: ... th Annual  Healthcare Conference on Thursday, May 30, 2013, ... , beginning at 9:20 a.m. Eastern Daylight Time. ... Amgen, will present at the conference. Live audio of the ... website, www.amgen.com , under Investors. A replay of the ...
(Date:5/23/2013)... , May 23, 2013 Nephros, Inc. ... stage medical device company that develops and sells high ... of its rights offering.  In addition, the concurrent temporary ... warrants expired on May 17, 2013. Nephros ... million from the rights offering.   A portion of the ...
Breaking Medicine Technology:Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
Cached News: